GSK stock edges higher as dengue antibody deal extends growth story
Published on 08/18/2026 at 20:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GSK plc (ISIN GB0009252882) stock hovered close to recent highs on August 18, 2026, with London-listed shares quoted around 1,861.00 GBX as the company secured an exclusive global license for the AID351 anti-dengue virus antibody.
The licensing agreement, announced on August 17, 2026, gives GSK worldwide rights to develop, manufacture and potentially commercialize AID351, reinforcing its vaccines and specialty medicines pipeline.
For investors, the combination of a fresh infectious disease asset and a stock price that has gained 2.0% since the start of 2026 underscores a steady, pipeline-supported equity story.
Pipeline expanded by dengue antibody deal
A key catalyst for GSK on August 18, 2026 was the exclusive license agreement signed with Chugai Pharmaceutical Co. Ltd. for AID351, an anti-dengue virus antibody.
Per a detailed report published on August 18, 2026, the deal grants GSK global rights to develop, manufacture and potentially commercialize AID351, positioning the company to target dengue fever, a mosquito-borne infection that remains prevalent in many emerging markets. A news release on the agreement noted that the contract was signed on August 17, 2026.
The same report highlighted that GSK shares in London ended 1.9% higher at 1,851.50 pence on the previous trading day, reflecting a positive initial reaction to the announcement before the stock consolidated around the 1,861.00 GBX mark on August 18, 2026.
A separate market overview showed GSK trading at 1,861.50 GBX on August 18, 2026, up 2.0% from 1,824.50 GBX at the start of the year, and up 1.53% year-to-date based on another real-time quote snapshot. One share price analysis reported the 2.0% gain since January 1, 2026, while a separate consensus page indicated a 1.53% rise from the start of the year.
Latest price levels and analyst consensus
Real-time data from August 18, 2026 showed GSK quoted at 1,860.25 GBX on the Cboe Europe platform, with a five-day gain of 0.28% and a year-to-date performance of 1.53% compared with the level at the start of 2026. A real-time quote snapshot illustrated the 1,860.25 GBX price alongside the year-to-date change.
Another market-data page focused on the Cboe listing presented a last close price of 18.52 GBP, with the same 1.53% year-to-date gain figure and a five-day change of 0.24%. The consensus overview tied this to a 1,859.50 GBX quote earlier on August 18, 2026.
From a US perspective, American depositary shares of GSK on the NYSE closed at $50.28 on August 17, 2026, gaining 1.53% on the day, with a modest post-market move to $50.35 reported later that evening. A US quote overview stated that the NYSE session ended at $50.28, followed by a post-market indication of $50.35 at 7:41 p.m. ET.
Consensus data pointed to an average target price of 21.61 GBP compared with the latest close of 18.52 GBP, implying upside potential of 16.7% from that reference level. The same market snapshot listed the 18.52 GBP last close and the 21.61 GBP average target, allowing investors to quantify the gap between current pricing and consensus expectations.
Investor context and year-to-date performance
For investors tracking performance, a market-data comparison showed that GSK stock was trading at 1,824.50 GBX on January 1, 2026 and had advanced to 1,861.50 GBX by mid-August 2026, a gain of 37.00 GBX or 2.0% over the period. The January-to-August comparison quantified this move.
Another data set reported a five-day change of 0.51% at a 1,861.00 GBX quote, while also indicating that the stock was 1.82% below its level five days earlier but 2.03% above its start-of-year value, highlighting a modestly positive longer-term trend with short-term fluctuations. The variation table showed the 1,861.00 GBX quote alongside the 0.51% five-day change and 2.03% year-to-date move.
In addition to the pipeline catalyst and share-price context, a regulatory filing dated August 18, 2026 presented director and person discharging managerial responsibilities share dealings at a price of $49.52, covering multiple volumes ranging from 73 shares to more than 2,200 shares. The filing overview listed $49.52 as the transaction price for several tranches on August 18, 2026.
These director-level transactions at a price point close to the prevailing US market quote add another data point to the equity story, even though they do not change fundamentals on their own.
Representative product focus: AID351 dengue antibody
Within GSK's broad portfolio of vaccines and specialty medicines, the newly licensed AID351 anti-dengue virus antibody stands out as a representative pipeline asset highlighted in August 2026.
Dengue fever poses a significant public-health challenge in many tropical and subtropical regions, and antibody-based approaches such as AID351 aim to neutralize the virus and reduce the severity of disease.
According to the licensing announcement, GSK will be responsible for advancing AID351 through clinical development and, if successful, manufacturing and commercialization, with the goal of adding a novel treatment option to its infectious disease franchise. The product-focused news item described AID351 as an anti-dengue virus antibody that could potentially address unmet medical needs.
For long-term shareholders, the progress of AID351 through development milestones will be one marker of how effectively GSK is leveraging external innovation to reinforce its internal R&D pipeline.
GSK stock at latest close
On the London market, GSK shares last closed at 1,851.50 pence on August 17, 2026, with subsequent real-time indications around 1,860.25 GBX on August 18, 2026.
On the NYSE, GSK's American depositary shares ended at $50.28 on August 17, 2026, with a small post-market uptick to $50.35 later that evening, illustrating a stable price level that broadly matches director transaction prices disclosed at $49.52 on August 18, 2026.
Fact box
Company: GSK plc
ISIN: GB0009252882
Ticker: GSK
Exchange: London Stock Exchange; ADR on NYSE
Price (as of August 17, 2026, 4:00 p.m. ET): $50.28 USD
Market cap: 101 billion GBP (as of August 18, 2026)
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: FTSE 100
